🔗 Share this article

The Nobel Prize in medical science was granted for transformative findings that clarify how the immune system targets harmful pathogens while protecting the healthy tissues.

A trio of esteemed researchers—from Japan Shimon Sakaguchi and American scientists Dr. Brunkow and Fred Ramsdell—received this accolade.

The research identified specialized "security guards" within the defense system that remove rogue immune cells capable of attacking the body.

The discoveries are now paving the way for innovative therapies for autoimmune diseases and malignancies.

These winners will share a prize fund worth 11m SEK.

Crucial Discoveries

"Their work has been decisive for comprehending how the body's defenses operates and the reason we do not all develop serious self-attack conditions," commented the chair of the Nobel Committee.

The trio's studies address a fundamental question: How does the defense system defend us from countless invaders while keeping our healthy cells intact?

Our body's protection system uses white blood cells that scan for indicators of disease, even viruses and bacteria it has never encountered.

Such defenders employ sensors—known as recognition units—that are produced randomly in a vast number of variations.

This gives the defense network the capacity to combat a wide array of threats, but the randomness of the mechanism inevitably creates immune cells that can attack the body.

Protectors of the Immune System

Researchers earlier understood that some of these problematic white blood cells were eliminated in the thymus—the site where immune cells develop.

This year's Nobel Prize honors the identification of regulatory T-cells—described as the body's "peacekeepers"—which travel through the system to disarm other immune cells that attack the healthy cells.

It is known that this mechanism fails in autoimmune diseases such as type-1 diabetes, MS, and rheumatoid arthritis.

The Nobel panel added, "The findings have established a novel area of research and accelerated the development of innovative therapies, for example for cancer and autoimmune diseases."

Regarding cancer, regulatory T-cells prevent the system from attacking the tumor, so research are focused on lowering their numbers.

For self-attack disorders, trials are exploring boosting T-reg cells so the organism is no longer being harmed. A similar approach could also be useful in reducing the chances of transplanted organ rejection.

Innovative Studies

Professor Sakaguchi, of Osaka University, conducted experiments on mice that had their immune gland extracted, leading to autoimmune disease.

The researcher demonstrated that introducing immune cells from healthy mice could stop the disease—suggesting there was a system for blocking defenders from harming the host.

Mary Brunkow, from the Institute for Systems Biology in Seattle, and Dr. Ramsdell, now at a biotech firm in a California city, were studying an inherited autoimmune disease in mice and people that resulted in the identification of a gene vital for how T-regs function.

"Their pioneering research has uncovered how the immune system is controlled by regulatory T cells, preventing it from mistakenly attacking the body's own tissues," commented a leading biological science expert.

"This work is a remarkable illustration of how basic physiological study can have broad consequences for human health."